Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Amgen Lays Out Plans For Rare Disease Portfolio Growth
Ex-US Push, Subcutaneous Dosing For Tepezza
Feb 23 2024
•
By
Mandy Jackson
Rare disease is one of four pillars for Amgen besides general medicine, inflammation and oncology • Source: Shutterstock
More from Rare Diseases
More from Scrip